PDF(Sci-hub)
Abstract：
UNASSIGNED: Several studies have reported the efficacy of cabazitaxel in cancer therapy; however, investigations of its safety are few. The aim of this study was to retrospectively analyze the efficacy and safety of cabazitaxel based on treatment outcome data.
UNASSIGNED: A questionnaire form on the use of cabazitaxel was mailed to hospitals associated with the Shinshu University. Responses were received from 11 institutions regarding 55 cases.
UNASSIGNED: Patients received a median of 4 courses of cabazitaxel treatment. Decreases in prostrate-specific antigen (PSA) were observed in 61.5% of cases with declines of 30%, 50%, and 90% in 36.5%, 23.0%, and 7.6% of cases, respectively. PSA progression-free survival was 5.0 months, and overall survival after the start of cabazitaxel was 13.0 months. Forty-five patients received postcabazitaxel treatment; 17 showed decreased PSA. Safety assessment indicated that white blood cell and neutrophil counts were significantly higher in the second than in the first course of treatment and Grade 3 to 4 leukopenia and neutropenia significantly decreased. Twenty-four subjects were aged ≥75 years; 79% of them had their doses reduced at the first administration. The mean dose was 20 mg/m2. However, there was no significant difference in the PSA progression-free survival between the ≥75-year-old and <75-year-old groups. Patients in the ≥75-year-old group, particularly those whose doses were not reduced, experienced several Grade 3 to 4 adverse effects. Ten patients discontinued treatment owing to adverse effects and systemic worsening.
UNASSIGNED: To use cabazitaxel effectively, starting administration as early as possible before disease progression is important, and even if Grade 3 to 4 leukopenia and neutropenia are observed during the first course, it is important to carefully maintain the dose. Even when treating elderly patients, reducing the dose does not reduce therapeutic efficacy. However, because this cohort experienced several ≥ Grade 3 adverse effects, a great deal of caution is required.
UNASSIGNED: A questionnaire form on the use of cabazitaxel was mailed to hospitals associated with the Shinshu University. Responses were received from 11 institutions regarding 55 cases.
UNASSIGNED: Patients received a median of 4 courses of cabazitaxel treatment. Decreases in prostrate-specific antigen (PSA) were observed in 61.5% of cases with declines of 30%, 50%, and 90% in 36.5%, 23.0%, and 7.6% of cases, respectively. PSA progression-free survival was 5.0 months, and overall survival after the start of cabazitaxel was 13.0 months. Forty-five patients received postcabazitaxel treatment; 17 showed decreased PSA. Safety assessment indicated that white blood cell and neutrophil counts were significantly higher in the second than in the first course of treatment and Grade 3 to 4 leukopenia and neutropenia significantly decreased. Twenty-four subjects were aged ≥75 years; 79% of them had their doses reduced at the first administration. The mean dose was 20 mg/m2. However, there was no significant difference in the PSA progression-free survival between the ≥75-year-old and <75-year-old groups. Patients in the ≥75-year-old group, particularly those whose doses were not reduced, experienced several Grade 3 to 4 adverse effects. Ten patients discontinued treatment owing to adverse effects and systemic worsening.
UNASSIGNED: To use cabazitaxel effectively, starting administration as early as possible before disease progression is important, and even if Grade 3 to 4 leukopenia and neutropenia are observed during the first course, it is important to carefully maintain the dose. Even when treating elderly patients, reducing the dose does not reduce therapeutic efficacy. However, because this cohort experienced several ≥ Grade 3 adverse effects, a great deal of caution is required.
摘要：
■一些研究报道了卡巴他赛在癌症治疗中的疗效；然而，对其安全性的调查很少。这项研究的目的是根据治疗结果数据回顾性分析卡巴他赛的疗效和安全性。
■关于使用卡巴他赛的调查表被邮寄到与信州大学相关的医院。收到了11个机构对55起案件的答复。
■患者平均接受4个疗程的卡巴他赛治疗。在61.5%的病例中观察到前列腺特异性抗原（PSA）的下降，下降了30%，50%,和36.5％中的90％，23.0%,7.6%的病例，分别。PSA无进展生存期为5.0个月,卡巴他赛开始后的总生存期为13.0个月。45例患者接受卡巴他赛后治疗；17例显示PSA降低。安全性评估表明，第二疗程的白细胞和中性粒细胞计数明显高于第一疗程，3至4级白细胞减少和中性粒细胞减少明显减少。24名受试者年龄≥75岁；其中79％的患者在第一次给药时剂量减少。平均剂量为20mg/m2。然而,≥75岁组和<75岁组的PSA无进展生存期无显著差异.≥75岁组的患者，特别是那些剂量没有减少的人，经历了几个3到4级的不良反应。10例患者因不良反应和全身恶化而停止治疗。
■要有效使用卡巴他赛，在疾病进展之前尽早开始给药很重要，即使在第一个疗程中观察到3至4级白细胞减少和中性粒细胞减少，小心保持剂量是很重要的。即使在治疗老年患者时，减少剂量不会降低治疗效果。然而,因为这个队列经历了几个≥3级的不良反应，需要非常谨慎。
■关于使用卡巴他赛的调查表被邮寄到与信州大学相关的医院。收到了11个机构对55起案件的答复。
■患者平均接受4个疗程的卡巴他赛治疗。在61.5%的病例中观察到前列腺特异性抗原（PSA）的下降，下降了30%，50%,和36.5％中的90％，23.0%,7.6%的病例，分别。PSA无进展生存期为5.0个月,卡巴他赛开始后的总生存期为13.0个月。45例患者接受卡巴他赛后治疗；17例显示PSA降低。安全性评估表明，第二疗程的白细胞和中性粒细胞计数明显高于第一疗程，3至4级白细胞减少和中性粒细胞减少明显减少。24名受试者年龄≥75岁；其中79％的患者在第一次给药时剂量减少。平均剂量为20mg/m2。然而,≥75岁组和<75岁组的PSA无进展生存期无显著差异.≥75岁组的患者，特别是那些剂量没有减少的人，经历了几个3到4级的不良反应。10例患者因不良反应和全身恶化而停止治疗。
■要有效使用卡巴他赛，在疾病进展之前尽早开始给药很重要，即使在第一个疗程中观察到3至4级白细胞减少和中性粒细胞减少，小心保持剂量是很重要的。即使在治疗老年患者时，减少剂量不会降低治疗效果。然而,因为这个队列经历了几个≥3级的不良反应，需要非常谨慎。
